Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cambridge Neuropsychological Test Automated Battery

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Cambridge Neuropsychological Test Automated Battery. Displaying page 1 of 1.
    EudraCT Number: 2014-003008-53 Sponsor Protocol Number: 80836009820016 Start Date*: 2014-12-10
    Sponsor Name:University Medical Center Utrecht
    Full Title: Clonidine Augmentation Therapy in Schizophrenia
    Medical condition: Schizophrenia, schizophreniform disorder, schizoaffective disorder
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002326-36 Sponsor Protocol Number: 2016-858 Start Date*: 2016-11-09
    Sponsor Name:Region Hovedstadens psykiatriske hospital
    Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T)
    Medical condition: Unipolar/bipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10045543 Unipolar depression LLT
    21.1 100000004873 10004936 Bipolar depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003557-21 Sponsor Protocol Number: LixiBrain01 Start Date*: 2019-02-06
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005536-17 Sponsor Protocol Number: UX007G-CL301 Start Date*: 2017-05-17
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, crossover study to assess the efficacy and safety of UX007 in the treatment of movement disorders associated with Glucose Transporter Type 1...
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10061032 Carbohydrate transport disorder LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003771-35 Sponsor Protocol Number: UX007G-CL201 Start Date*: 2014-02-11
    Sponsor Name:Ultragenyx Pharmaceutical Inc
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adaptive Study to Assess the Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type 1 Deficiency Syndrome
    Medical condition: Glucose Transporter Type 1 deficiency syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10039911 Seizures (incl subtypes) HLGT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) FR (Ongoing) HU (Completed) ES (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001549-42 Sponsor Protocol Number: STH19379 Start Date*: 2020-03-27
    Sponsor Name:Sheffield Teaching Hospitals
    Full Title: A multicentre, randomised controlled trial to evaluate the efficacy of autologous haematopoietic stem cell transplantation versus alemtuzumab or ocrelizumab in relapsing remitting multiple sclerosis.
    Medical condition: Highly active relapsing remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-001976-75 Sponsor Protocol Number: 20130385 Start Date*: 2014-09-11
    Sponsor Name:Amgen Inc
    Full Title: A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Back...
    Medical condition: Dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10020604 Hypercholesterolemia LLT
    17.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) IT (Completed) FI (Completed) EE (Completed) SK (Completed) LV (Completed) DE (Completed) LT (Completed) CZ (Completed) PT (Completed) BE (Completed) HU (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004172-30 Sponsor Protocol Number: PREPARE Start Date*: 2021-10-13
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemothe...
    Medical condition: Breast cancer patients scheduled for treatment with paclitaxel chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004023-24 Sponsor Protocol Number: PRETEC-EPO Start Date*: 2016-12-15
    Sponsor Name:Copenhagen Affective Disorder research Center (CADIC), Psychiatric Centre Copenhagen, Rigshospitalet
    Full Title: Effect of erythropoietin (EPO) on cognitive function and frontal lobe activity in patients with bipolar disorder and unipolar depression in remission (PRETEC-EPO)
    Medical condition: Bipolar disorder and unipolar depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    21.1 10037175 - Psychiatric disorders 10045543 Unipolar depression LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-003405-26 Sponsor Protocol Number: NF1-EXCEL Start Date*: 2014-09-03
    Sponsor Name:Erasmus MC
    Full Title: The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)
    Medical condition: Neurofibromatosis type 1
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004850 10029270 Neurofibromatosis, type 1 (von Recklinghausen's disease) LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) BE (Completed) DK (Prematurely Ended) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004012-13 Sponsor Protocol Number: WN22018 Start Date*: 2009-03-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio multicéntrico de búsqueda de dosis, randomizado, doble ciego, controlado con placebo, con grupos de tratamiento paralelos, de RO5313534 administrado como tratamiento adyuvante a donepezilo ...
    Medical condition: Enfermedad de Alzheimer leve a moderada Mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) SK (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000823-15 Sponsor Protocol Number: NEUPRODEX Start Date*: 2013-12-23
    Sponsor Name:Charité – Universitätsmedizin Berlin
    Full Title: Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery
    Medical condition: The drug Dexmedetomidine will be investigated in patients (men and women) undergoing elective cardiac or abdominal surgery. The study medication will be administered perioperatively by intravenous ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005015-28 Sponsor Protocol Number: 1289.6 Start Date*: 2014-10-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment perio...
    Medical condition: Patients with schizophrenia on stable antispychotic treatment
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10039634 Schizophrenia residual LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003466-33 Sponsor Protocol Number: 1103-011 Start Date*: 2013-05-17
    Sponsor Name:Mental Health Services North Holland North
    Full Title: Memantine Add-On Therapy to Clozapine
    Medical condition: Cognitive functioning, severity of psychopathology and treatment response (positive symptoms and negative symptoms of schizophrenia), depressive symptoms, social cognition, obsessive-compulsive sy...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001666-35 Sponsor Protocol Number: Kar-013 Start Date*: 2023-01-05
    Sponsor Name:Karuna Therapeutics, Inc.
    Full Title: An Open Label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003189-16 Sponsor Protocol Number: R727-CL-1532 Start Date*: 2016-12-22
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients with Heterozygous Familial Hypercholesterolemia or with Non-Familial H...
    Medical condition: Heterozygous Familial Hypercholesterolemia or Non-Familial Hypercholesterolemia with High and Very High Cardiovascular Risk
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.1 100000004861 10020604 Hypercholesterolemia LLT
    20.0 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    20.0 10007541 - Cardiac disorders 10007649 Cardiovascular disorder PT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000821-29 Sponsor Protocol Number: SPD503-401 Start Date*: 2020-11-19
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...
    Medical condition: Attention-deficit/hyperactivity disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Trial now transitioned) SE (Trial now transitioned) AT (Prematurely Ended) ES (Ongoing) BE (Trial now transitioned) PT (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019895-66 Sponsor Protocol Number: WN25203 Start Date*: 2011-07-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 on Cognition and Function in Prodromal Alzheimer's Disease ...
    Medical condition: Prodromal Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) IT (Completed) ES (Completed) FI (Completed) NL (Completed) DK (Completed) CZ (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 19:11:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA